Skip to content

Search

A marked shift in innate and adaptive immune response in chinese immigrants living in a western environment

There is a marked shift in innate and adaptive immune responses in Chinese immigrants after living in a Western environment for several years

IgE and T-cell responses to house dust mite allergen components

Recent studies with synthetic peptides representing allergens and non-allergenic house dust mite proteins now offer new research avenues on HDM induced immune responses

Blueprint for the House Dust Mite

The completeness of the coverage of a genome assembly is a critical starting point for all genomic projects so considerable attention is given to the sequencing metrics, which showed high indicators of success.

Structural and IgE binding analyses of recombinant Der p 2 expressed from the hosts Escherichia coli and Pichia pastoris

The house dust mite allergen Der p 2 is one of the most important indoor allergens associated with allergic disease.

House dust mite allergens in asthma and allergy

IgE antibodies in house dust mite (HDM) allergy follow a predictable pattern. Half are directed against two dominant allergens and the remainder largely against

Early aberrant antibody responses of aeroallergen sensitised people to subclinical bacterial infection

Early aberrant antibody responses, aeroallergen sensitised people, subclinical bacterial infection

Investigations into the role of ST2 in acute asthma in children

This study investigated the potential role of ST2 in children with acute asthma.

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown.

Clinical Management of Staphylococcus aureus Bacteremia in Neonates, Children, and Adolescents

Staphylococcus aureus is a common cause of community and health care-associated bacteremia, with authors of recent studies estimating the incidence of S aureus bacteremia (SAB) in high-income countries between 8 and 26 per 100 000 children per year. Despite this, <300 children worldwide have ever been randomly assigned into clinical trials to assess the efficacy of treatment of SAB.

Impact of the COVID-19 Pandemic on Tuberculosis Control

Throughout history, pandemics of viral infections such as HIV, Ebola and Influenza have disrupted health care systems, including the prevention and control of endemic diseases. Such disruption has resulted in an increased burden of endemic diseases in post-pandemic periods.